146 related articles for article (PubMed ID: 21165233)
1. Visual prognosis of retinoblastoma in the posterior pole treated with primary chemotherapy plus local treatments.
Kim JM; Kim JH; Kim SJ; Park KD; Shin HY; Ahn HS; Yu YS
Korean J Ophthalmol; 2010 Dec; 24(6):347-52. PubMed ID: 21165233
[TBL] [Abstract][Full Text] [Related]
2. Visual outcome in macular retinoblastoma treated with primary chemotherapy.
Balasubramanya R; Pushker N; Bajaj MS; Rani A; Ghose S; Arya LS
Ophthalmologica; 2003; 217(6):417-21. PubMed ID: 14573975
[TBL] [Abstract][Full Text] [Related]
3. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation.
Schefler AC; Cicciarelli N; Feuer W; Toledano S; Murray TG
Ophthalmology; 2007 Jan; 114(1):162-9. PubMed ID: 17070578
[TBL] [Abstract][Full Text] [Related]
4. Prospective phase II study of children affected by bilateral intraocular retinoblastoma with macular involvement of both eyes or in the only preserved eye. Macular tumor control, eye preservation rate, and visual outcome.
Russo I; Levy-Gabriel C; Dupont A; Lumbroso-Le Rouic L; Cassoux N; Desjardins L; Bertozzi AI; Coze C; Doz F; Savignoni A; Aerts I
Pediatr Blood Cancer; 2021 Jan; 68(1):e28721. PubMed ID: 33098751
[TBL] [Abstract][Full Text] [Related]
5. Long-term visual outcome following chemoreduction for retinoblastoma.
Demirci H; Shields CL; Meadows AT; Shields JA
Arch Ophthalmol; 2005 Nov; 123(11):1525-30. PubMed ID: 16286614
[TBL] [Abstract][Full Text] [Related]
6. Foveal microanatomy documented by SD-OCT following treatment of advanced retinoblastoma.
Samara WA; Pointdujour-Lim R; Say EA; Shields CL
J AAPOS; 2015 Aug; 19(4):368-72. PubMed ID: 26235789
[TBL] [Abstract][Full Text] [Related]
7. A 10-year experience of outcome in chemotherapy-treated hereditary retinoblastoma.
Bartuma K; Pal N; Kosek S; Holm S; All-Ericsson C
Acta Ophthalmol; 2014 Aug; 92(5):404-11. PubMed ID: 24119165
[TBL] [Abstract][Full Text] [Related]
8. Chemoreduction for unilateral retinoblastoma.
Shields CL; Honavar SG; Meadows AT; Shields JA; Demirci H; Naduvilath TJ
Arch Ophthalmol; 2002 Dec; 120(12):1653-8. PubMed ID: 12470138
[TBL] [Abstract][Full Text] [Related]
9. Restoration of foveal anatomy and function following chemoreduction for bilateral advanced retinoblastoma with total retinal detachment.
Shields CL; Materin MA; Shields JA
Arch Ophthalmol; 2005 Nov; 123(11):1610-2. PubMed ID: 16286630
[No Abstract] [Full Text] [Related]
10. Vision and visual potential for perifoveal retinoblastoma after optical coherence tomographic-guided sequential laser photocoagulation.
Soliman SE; VandenHoven C; Mackeen LD; Gallie BL
Br J Ophthalmol; 2019 Jun; 103(6):753-760. PubMed ID: 29976784
[TBL] [Abstract][Full Text] [Related]
11. Predictors of long-term visual outcome after chemoreduction for management of intraocular retinoblastoma.
Narang S; Mashayekhi A; Rudich D; Shields CL
Clin Exp Ophthalmol; 2012; 40(7):736-42. PubMed ID: 22300311
[TBL] [Abstract][Full Text] [Related]
12. Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre.
Künkele A; Jurklies C; Wieland R; Lohmann D; Bornfeld N; Eggert A; Schulte JH
Br J Ophthalmol; 2013 Oct; 97(10):1277-83. PubMed ID: 23863458
[TBL] [Abstract][Full Text] [Related]
13. Management and outcome of retinoblastoma with vitreous seeds.
Manjandavida FP; Honavar SG; Reddy VA; Khanna R
Ophthalmology; 2014 Feb; 121(2):517-24. PubMed ID: 24572675
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma.
Zage PE; Reitman AJ; Seshadri R; Weinstein JL; Mets MB; Zeid JL; Greenwald MJ; Strauss LC; Goldman S
Pediatr Blood Cancer; 2008 Mar; 50(3):567-72. PubMed ID: 17729249
[TBL] [Abstract][Full Text] [Related]
15. Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma.
Berry JL; Bechtold M; Shah S; Zolfaghari E; Reid M; Jubran R; Kim JW
Ophthalmology; 2017 Dec; 124(12):1817-1825. PubMed ID: 28655537
[TBL] [Abstract][Full Text] [Related]
16. The treatment of retinoblastoma with four-drug regimen including cisplatin, etoposide, vincristine, and cyclophosphamide.
Varan A; Kiratli H; Aydın B; Tarlan B; Poyraz CB; Akyüz C; Büyükpamukçu M
Pediatr Hematol Oncol; 2012 Sep; 29(6):529-37. PubMed ID: 22759219
[TBL] [Abstract][Full Text] [Related]
17. Factors predictive of long-term visual outcomes of Group D eyes treated with chemoreduction and low-dose IMRT salvage: the Children's Hospital Los Angeles experience.
Berry JL; Jubran R; Wong K; Lee TC; Murphree AL; Kim JW
Br J Ophthalmol; 2014 Aug; 98(8):1061-5. PubMed ID: 24671926
[TBL] [Abstract][Full Text] [Related]
18. Visual outcomes following intraophthalmic artery melphalan for patients with refractory retinoblastoma and age appropriate vision.
Tsimpida M; Thompson DA; Liasis A; Smith V; Kingston JE; Sagoo MS; Reddy MA
Br J Ophthalmol; 2013 Nov; 97(11):1464-70. PubMed ID: 24037611
[TBL] [Abstract][Full Text] [Related]
19. Preservation of retinoblastoma group E eyes with neovascular glaucoma using intravenous chemotherapy: risk factors and outcomes.
Rao R; Honavar SG; Reddy VP
Br J Ophthalmol; 2019 Dec; 103(12):1856-1861. PubMed ID: 30796055
[TBL] [Abstract][Full Text] [Related]
20. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis.
Suzuki S; Yamane T; Mohri M; Kaneko A
Ophthalmology; 2011 Oct; 118(10):2081-7. PubMed ID: 21715012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
